IQVIA Holdings Inc. (IQV)
NYSE: IQV · Real-Time Price · USD
154.61
+0.51 (0.33%)
At close: Jun 18, 2025, 4:00 PM
156.50
+1.89 (1.22%)
After-hours: Jun 18, 2025, 7:46 PM EDT
IQVIA Holdings Employees
IQVIA Holdings had 88,000 employees as of December 31, 2024. The number of employees increased by 1,000 or 1.15% compared to the previous year.
Employees
88,000
Change (1Y)
1,000
Growth (1Y)
1.15%
Revenue / Employee
$176,102
Profits / Employee
$15,159
Market Cap
26.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 88,000 | 1,000 | 1.15% |
Dec 31, 2023 | 87,000 | 1,000 | 1.16% |
Dec 31, 2022 | 86,000 | 7,000 | 8.86% |
Dec 31, 2021 | 79,000 | 9,000 | 12.86% |
Dec 31, 2020 | 70,000 | 3,000 | 4.48% |
Dec 31, 2019 | 67,000 | 9,000 | 15.52% |
Dec 31, 2018 | 58,000 | 3,000 | 5.45% |
Dec 31, 2017 | 55,000 | 5,000 | 10.00% |
Dec 31, 2016 | 50,000 | 13,900 | 38.50% |
Dec 31, 2015 | 36,100 | 3,500 | 10.74% |
Dec 31, 2014 | 32,600 | 4,400 | 15.60% |
Dec 31, 2013 | 28,200 | 788 | 2.87% |
Dec 31, 2012 | 27,412 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
IQV News
- 3 days ago - IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement' - Business Wire
- 8 days ago - IQVIA Launches New AI Agents for Life Sciences and Healthcare - Business Wire
- 9 days ago - IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap? - Benzinga
- 17 days ago - IQVIA Announces Pricing of Senior Notes - Business Wire
- 17 days ago - IQVIA Announces Offering of Senior Notes - Business Wire
- 23 days ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 4 weeks ago - IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Business Wire
- 5 weeks ago - IQVIA: Q1 Earnings Support Steady Optimism - Seeking Alpha